HLS Therapeutics Inc. (OTCMKTS:HLTRF) Short Interest Update

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a significant increase in short interest in August. As of August 14th, there was short interest totaling 1,646 shares, an increase of 269.1% from the July 30th total of 446 shares. Based on an average daily volume of 2,461 shares, the short-interest ratio is presently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Strong Buy”.

HLS Therapeutics Stock Performance

Shares of OTCMKTS HLTRF opened at $2.76 on Friday. The company has a 50-day moving average price of $2.96 and a 200-day moving average price of $3.16. HLS Therapeutics has a 1 year low of $2.65 and a 1 year high of $4.02.

About HLS Therapeutics

HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.

The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.